IonQ Unveils New Enterprise-Grade Quantum OS and Hybrid Services Suite
2.12.2024 22:05:00 CET | Business Wire | Press release
Full stack development approach drives enterprise-grade capabilities, enabling improved quantum functionality for commercial applicationsIonQ Quantum OS drives an average reduction of over 50 percent in on-system classical overhead, improving time to solution for quantum workloads
IonQ (NYSE: IONQ), a leader in the quantum computing and networking industry, today announced the launch of its quantum operating system, now called IonQ Quantum OS, and a collection of new capabilities named IonQ Hybrid Services suite. These technologies will greatly advance performance and utility of quantum computing for enterprise customers.
IonQ Quantum OS is a nearly ground-up rewrite of IonQ’s original quantum operating system. Designed and built with a flexible and modular architecture, it is designed to scale and adapt with IonQ’s hybrid quantum computing ecosystem and power IonQ’s current and future flagship quantum computers, including IonQ Forte and IonQ Forte Enterprise.
Designed for improved performance, IonQ Quantum OS dramatically improves time-to-solution, including:
- An average reduction of over 50 percent in on-system classical overhead (compared to identical workloads run on IonQ Forte before the improvements were deployed).
- An 85 percent reduction in cloud and network overhead of workloads submitted through the IonQ Cloud.
- Up to 100x improved accuracy in an expanded error mitigation and compilation suite.
- Enhanced calibration, automation, and control software and firmware to optimize qubit and gate performance and adjust for systemic drifts, resulting in better algorithmic performance.
IonQ Quantum OS also offers enterprise-grade security through improved observability and enhanced interoperability across on-premise hardware and software solutions. These improvements provide customers with new options for securely integrating quantum computing into their stack. IonQ Quantum OS has been running commercial workloads on IonQ Forte since summer 2024 and will soon be operational in controlling IonQ Forte Enterprise as it comes online in IonQ’s Basel, Switzerland data center.
“We designed our Quantum OS not only to address the complex demands of today’s enterprises but to scale seamlessly as their needs evolve,” said Peter Chapman, President and CEO of IonQ. “Our goal is to empower enterprise customers to unlock new possibilities and drive innovation with quantum computing.”
Showcased as an early preview with NVIDIA at SuperCompute 2024, IonQ’s new Hybrid Services suite is designed to enable seamless development and deployment of hybrid workloads that integrate IonQ quantum computers with high-performance classical resources over the cloud. This suite introduces significant advancements to enhance the speed, performance, and usability of quantum workloads, including:
- The Workload Management & Solver Service, a quantum developer toolkit that offers capabilities to efficiently move hybrid workloads to the cloud. This service features a quantum function and hybrid solver designed to help developers simplify the process of manually building circuits and iterative algorithms by packaging them into portable workloads to be executed and enhanced based on their needs.
- A new scheduling feature, Sessions, built on top of IonQ’s Fair Share scheduling engine, is designed to streamline provisioning of QPU time so that iterative and resource-intensive workflows run with minimal wait and interruption. Sessions also provides expanded support for offerings from IonQ’s cloud partners, including Amazon Braket Hybrid Jobs and Azure Quantum Sessions.
- The all-new IonQ SDK allows for seamless, simple, and reliable integration with IonQ Quantum Cloud API and IonQ Hybrid Services.
IonQ Hybrid Services suite is already accelerating the development of real-world, commercial quantum hybrid applications with customers. IonQ recently worked with Oak Ridge National Laboratory (ORNL) to implement a beta version of Hybrid Services to support the development of a NISQ-friendly quantum algorithm, which accelerates time-to-solution for hard optimization problems.
To learn more about IonQ and its latest system news and business developments, visit https://ionq.com.
About IonQ
IonQ, Inc. is a leader in quantum computing that delivers high-performance systems capable of solving the world’s largest and most complex commercial and research use cases. IonQ’s current generation quantum computer, IonQ Forte, is the latest in a line of cutting-edge systems, boasting 36 algorithmic qubits. The company’s innovative technology and rapid growth were recognized in Fast Company’s 2023 Next Big Things in Tech List and Deloitte’s 2023 Technology Fast 500™ List, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.
IonQ Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words ”will,” “expect,” and other similar expressions are intended to identify forward-looking statements. These statements include those related to the expected benefits of IonQ’s quantum operating system and hybrid services suite, the ability for third parties to implement IonQ’s offerings to increase their quantum computing capabilities, IonQ’s quantum computing capabilities and plans, the commercial relevance and advantages of applications, and the performance, scalability, accessibility, ease of use, capacity, power, speed, latency, quality, and reliability of IonQ’s quantum computing offerings. IonQ’s quantum computing capabilities and plans, improved efficiency and speed of quantum workloads and algorithms run on IonQ’s quantum computers, and the scalability of IonQ’s quantum computing offerings. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: IonQ’s ability to implement its technical roadmap; changes in the competitive industries in which IonQ operates; changes in laws and regulations affecting IonQ’s business; IonQ’s ability to implement its business plans, forecasts and other expectations, identify and realize partnerships and opportunities, and to engage new and existing customers; and events that may impact the security, quality and reliability of IonQ’s technology. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ’s most recent Quarterly Report on Form 10-Q and other documents filed by IonQ from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations. IonQ may or may not choose to practice or otherwise use the inventions described in the issued patents in the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241202941767/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom